Kai Lin

Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA.

Permeon Biologics, Inc. develops intracellular biotherapeutics platform to enhance drug delivery. Its intraphilin technology platform leverages research on remodeling the surfaces of proteins to permit cell penetration without losing their structure or activity; and enables functional proteins to replace or restore defective pathways inside cells that cause disease. The company was founded by Douglas G. Cole, David R. Liu, John W. Ripple, and Noubar B. Afeyan in 2008 and is headquartered in Cambridge, MA.